The Cutaneous Connection: Enhancing Vitiligo Care With Nanette Silverberg, MD
In today’s podcast, Silverberg discusses topical therapeutics for vitiligo and clinical excellence.
Amber Blair, PA-C, Shares Innovative Insights as SDPA President-Elect
Renata Block, MMS, PA-C, and Amber Blair, MMS, PA-C, discuss the gratification of helping patients and the excitement of being on the cutting edge of research.
Lebrikizumab Maintains EASI 90 Responses up to 38 Weeks After Discontinuation
The post-hoc analysis evaluated the relationship between lebrikizumab serum concentration levels and sustained clinical response after lebrikizumab discontinuation.
Antimicrobial Resistance: Challenges and Potential Solutions
Stephen Tyring, MD, PhD, MBA, covers the burden of antimicrobial resistance and the need for alternative treatments.
Beyond Aesthetics: The Vital Role of Nails in Health
Martin Zaiac, MD, gave insight on potential risks associated with manipulation of nails, hygiene, and when it is necessary to see a specialist.
Laura Bush on Dermatology PA Advancements
Laura Bush reflects on her term as SDPA president, discussing achievements, challenges, and the future of dermatology PAs in health care.
Modern Dermatology: Advanced Meds and Social Media Myths
Rob Casquejo, PA-C, spoke with Dermatology Times on new and upcoming medications, addressing unmet needs, and social media misinformation.
Addressing the Health Impacts of a Changing Climate
Ethan Sims, MD, spoke with Dermatology Times on having positive conversations, cutting down on waste, and how to get involved in change.
Alice Gottlieb, MD, PhD: Preventing Pain and Disability in Psoriatic Disease
Gottlieb reviews her lecture from the Society for Investigative Dermatology Annual Meeting.
What Conferences Are You Planning to Attend in Quarter 3 of 2024?
Ahead of the next 3 months of the year, Dermatology Times wants to know what conferences and meetings you plan to attend between July and September. Share your thoughts with us by June 26.
Conference Recap: 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema
Catch up on all clinical pearls from the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.
Battle of the Two Titans: When to Progress AD Patients to Systemic Therapy
Jonathan Silverberg, MD, PhD, MPH, and Melinda Gooderham, MSc, MD, FRCPC, debated which patients are a contender for systemic therapy.
Late-Breaker: Positive 52-week Data for Rademikibart in Patients with AD
The data, presented at RAVE 2024, continued a positive trend, building upon strong phase 1 results of rademikibart for patients with AD.
Prioritizing Itch and Sleep Improvement in Atopic Dermatitis
Gil Yosipovitch, MD, addresses the severity of chronic itch and sleep disturbances in patients with atopic dermatitis.
Day 2 Recap: 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
Catch up on coverage from the last day of the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.
Late-Breaker: Upadacitinib Demonstrates Superiority Over Dupilumab in All Ranked Secondary End Points of Head-to-Head AD Study
The phase 3b/4 LEVEL-UP study assessed adolescents and adults with moderate to severe atopic dermatitis.
Late-Breaker: Roflumilast Cream 0.15% Demonstrates Continued Improvement in AD Symptoms Through 56 Weeks
Roflumilast cream 0.15% is being evaluated for patients with mild to moderate atopic dermatitis down to 6 years.
Addressing Itch and Remission in Atopic Dermatitis
Raj Chovatiya, MD, PhD, discusses how approved AD therapeutics currently address itch and whether any therapeutics will eventually have a remittive effect.
Looking Ahead to Advancements in Vitiligo and Atopic Dermatitis
David Rosmarin, MD, shares key points from phase 3 data of ruxolitinib for vitiligo, as well as highlights the potential for targeting the STAT pathway in upcoming atopic dermatitis therapeutics.
Exploring New Pathways in Atopic Dermatitis
Melinda Gooderham, MSc, MD, FRCPC, discusses potential new biologics for atopic dermatitis that target IL-22, IL-33, OX40, and more.